Agricultural Biotechnology. Annual 2016. Korea - Republic of Дек. 13, 2016
In February 2016, Korea revised the Food Sanitation Act, expanding mandatory biotech labeling to include all products with detectable biotech ingredients. The Ministry of Food and Drug Safety (MFDS) is still finalizing the Labeling Guidelines for Biotech Food, which will provide details on how to comply with the Food Sanitation Act revision. The Act's labeling requirement will go into effect on February 4, 2017. In a setback to Korean biotech crop development, strong concern voiced by local farmers and nongovernmental organizations (NGOs), seems to have stopped Korea's first genetically engineered (GE) rice product from advancing to the risk assessment stage. In trade policy, after detection of GE wheat in Washington State in July 2016, Korea began testing all incoming U.S. wheat and wheat flour to confirm the absence of unapproved GE events. There have been no positive detections.
SECTION I. EXECUTIVE SUMMARY
Korea is heavily dependent on imported food (except rice) and feed grains. Only a limited number of food products are made from biotech ingredients due to negative consumer sentiment towards biotechnology, whereas the bulk of livestock feed is made from biotech corn and soybean meal. The United States and Brazil were the two top GE grain exporters to Korea in 2015 and 2016.
MFDS (formerly KFDA) revised the Food Sanitation Act on February 3, 2016, to expand mandatory biotech labeling to any food products that contain detectable biotech ingredients. After a long battle between law makers, NGOs who demanded European Union (EU)-like labeling standards, and the local food industry who objected to any expanded labeling, MFDS negotiated a revision that does not require biotech labeling for non-detectable products but does expand mandatory labeling to food products that contain detectable biotech ingredients beyond the top five ingredients. Cooking oils and syrups will continue to be exempt from mandatory biotech labeling. This revision shall go into effect on February 4, 2017. Guidelines related to how these new requirements can be met by producers have yet to be published by MFDS.
After the detection of GE wheat in the U.S. State of Washington in July 2016, MFDS started testing all U.S. origin wheat and wheat flour to confirm the absence of MON71800 and MON71700. The Ministry of Agriculture, Food & Rural Affairs (MAFRA) is also testing feed-quality wheat.Imports of biotech grains as well as GE animals are regulated under the Living Modified Organism (LMO) Act. In December 2012, the Ministry of Trade, Industry and Energy (MOTIE) announced its first revision to the LMO Act, revising implementing regulations, and providing a definition of stacked events. Despite the revisions, the regulations still do not make the fundamental distinction between biotech for food, feed and processing (FFP), and biotech seed; do not eliminate the redundant risk assessment process; and do not provide a workable definition of adventitious presence. MOTIE also revised the Enforcement Decree, Enforcement Regulations, and the Consolidated Notice, in 2014. Despite a few positive changes in the revised implementing regulations, concerns about redundancies in the consultation review process or excessive data requirements have not been fully addressed.
While sensitivities remain with biotech food, consumers are much more comfortable with non-agriculture uses, such as pharmaceutical treatments. Generating local farmers' support in adopting and actively use this technology will be key to increasing consumer confidence in biotech food and livestock products.
In 2016, MAFRA announced a plan called “2016 Promotion of Science and Technology for Agriculture, Forestry and Food." According to this R&D plan, MAFRA will invest 111 billion Korean won (approximately 110 million US dollars) in R&D of agri-bio resources such as production of pigs producing bio-organs, production of special purpose dogs using cloning technology (sniffing dogs), stem cell production technology, and other related projects.
CHAPTER 1: PLANT BIOTECHNOLOGY
Part A. Production and Trade
A) Product Development
The development of biotech, or GE crops, also known as living modified organisms—LMOs, in Korea is led by various government agencies, universities, and private entities. Research is mainly focused on second and third generation traits, such as drought and disease resistance, nutrient enrichment, transformation techniques, and gene expression. The Rural Development Agency (RDA) approved a total of 371 research cases for field trials conducted by RDA's designated evaluation entities and private entities in 2016.
In May 2015, the RDA released results of the first phase for the Next Generation Bio-Green 21 Project, which aims to develop fundamental technology and commercialize such technology. With a total investment of 271.4 billion won (approximately $236 million), RDA decoded genomes for 9 items including pepper and ginseng and developed anthracnose resistant pepper and other products between 2011 and 2014. RDA will invest another 300 billion won (approximately $260 million) by 2020 in order to commercialize technology that has been and will be developed.
RDA has 170 events in 17 different varieties of crops under development. These crops include some of the following: resveratrol enriched rice, vitamin A enriched rice, insect resistant rice, environmental stress tolerant rice, virus resistant pepper, vitamin E enriched beans, insect resistant beans, herbicide tolerant vent grass, virus resistant potatoes and Chinese cabbage, watermelon, sweet potato, and apples. Safety assessment data is currently being generated for six events in three crops; four rice, one pepper, and one cabbage and five events in flowers and vent grass. A local university developed anherbicide tolerance vent grass under RDA's Next Generation Bio-Green 21 Project that was submitted to RDA for an environmental risk assessment (ERA) in December 2014. RDA also developed rice enriched with resveratrol, known to be an antioxidant polyphenol preventing heart disease, as well as virus resistant pepper. When RDA announced its plan to submit the ERA dossier for rice enriched with resveratrol in 2015, there was significant pushback from local NGOs and rice farmers, who were concerned that field trials of GE rice would contaminate conventional rice fields. Thus, NGOs had daily protests in front of RDA and asked RDA to stop GE rice development. Bowing to this pressure, RDA decided not to use this rice for food use. They plan instead to produce this GE rice in a contained environment and to limit the use of resveratrol produced by GE rice only for industrial purposes, such as pharmaceutical or cosmetics. Despite RDA's accommodative efforts, local NGOs continue to call for cessation of field trials and GE rice production generally in Korea.
A team from a government research institute developed biotech sweet potatoes that are resistant to drought and saline to surmount the effects of desertification. The institute succeeded in growing the sweet potatoes in China's Kubuchi Desert and Kazakhstan, two of the largest semi-arid areas in Northeast Asia. They also started the genome decoding process for sweet potatoes in 2014 in coordination with Chinese and Japanese researchers. With decoded information, the team aims to grow a large amount of biotech sweet potatoes in areas affected by desertification in China, the Middle East, and Africa.
The private sector is also doing research on biotech crops. According to industry estimates, approximately 60 varieties are currently under development, although most of them are still at the laboratory stage. The one noteworthy exception is the virus resistant pepper, which has made progress and researchers are generating a dossier for an ERA.
Although significant research has been done, the soonest one of these crops (most likely herbicide resistant vent grass or resveratrol enriched rice) could finish the regulatory review process is five years. Commercialization is expected to take much longer and will be entirely dependent on the task of getting Korean farmers to first recognize the benefits and adopt this technology. Generating farmers' support to actively use this technology is considered key to increasing consumer confidence in biotech food.
B) Commercial Production
Despite substantial investment, Korea has yet to commercially produce any biotech crops.
Korea does not export any biotech crops as Korea does not commercially produce any biotech crops.
Korea imports biotech crops and products for food, feed and processing, but not for propagation. The United States, closely followed by and sometimes surpassed by Brazil, is usually the largest supplier of biotech grains and oilseeds to the Korean market. In the year through August 2016, the United States is the largest supplier followed by Brazil and Argentina.
In 2015, Korea imported a total of 10.3 million metric tons of corn, which consisted of 8.2 million metric tons for feed and 2.1 million metric tons for processing. Imports from the United States reached 3.5 million metric tons, or 34 percent of the total. Imports of U.S. corn were comprised of 3.1 million metric tons for animal feed, which was nearly all biotech corn. The remaining 0.4 million metric tons of U.S. corn was used for processing of which nearly 90 percent were biotech.
Imported biotech processing corn is generally used to make products like high fructose corn syrup (HFCS) or corn oil. Both are exempt from biotech labeling requirements since the biotech protein is undetectable. Despite mounting pressure from local NGOs and consumer groups, some processors continue using biotech corn since it is more affordable and easier to secure on the world market than conventional corn. Meanwhile, the processors producing flour, grits and flakes are importing identity preserved (IP) conventional corn from a variety of international suppliers.
In 2015, Korea imported a total of 1.3 million metric tons of soybeans, three-quarters of which were used for crushing. The United States was the second largest soybean supplier, exporting 529,648 metric tons, which represents about 40 percent of all imports. Of that amount, 279,291 metric tons were used for crushing and 250,357 metric tons for food processing/sprouting. Brazil was the largest soybean supplier to Korea in 2015, exporting 745,814 metric tons.
Supplementing domestically produced meal, Korea imported 1.9 million metric tons of soybean meal in 2015. The United States exported 1,817 metric tons, accounting for 0.1 percent of total imports. Soybean oil is exempt from biotech labeling requirements since the modified protein is undetectable. Soybeans for food processing are used in products such as tofu, bean paste, and bean sprouts, and are IP-handled, non-biotech beans.
E) Food Aid
South Korea is not a food aid recipient. South Korea has provided intermittent food aid to North Korea depending on the prevailing political conditions. Korea participates in the ASEAN Plus Three Emergency Rice Reserve (APTERR), which was established in 2013 to provide member countries with rice in the event of natural disasters. Korea provided 90,000 MT of rice to date out of 150,000 MT that they promised.
F) Trade Barriers
Liberty Link Rice (LLRice): In 2013, MFDS discontinued mandatory arrival LLRice testing for all incoming US rice shipments, which had been required after LL's presence was discovered in 2006. Instead, MFDS will select one quarter of the year to conduct LLRice testing for all incoming U.S. rice shipments for that given quarter under its monitoring program. MAFRA also removed requirements for a statement issued by USDA's Grain Inspection, Packers and Stockyards Administration (GIPSA) on laboratories participating in GIPSA's proficiency program and a “non-GMO" (genetically modified organism) certificate issued by one of the participating laboratories in 2014. Currently, only one test is required by the Korean state trading entity, aT, prior to loading. MON71800 & MON71700 Wheat Event: After the detection of GE wheat (MON71800) in the state of Oregon in May 2013 and the detection of GE wheat (MON71700) in Washington in July 2016, MFDS now conducts mandatory testing applicable to any wheat or wheat flour shipments originating from the United States in order to confirm the absence of both MON71800 and MON71700. For wheat for feed use, MAFRA tested imported wheat for years prior to the finding of the GE wheat in Oregon and Washington. After the finding, MAFRA expanded the number of samples of U.S. origin wheat for feed use to test for the presence of GE wheat. Testing conducted by the Korean government to date has all turned out negative.
Event 32 Test on U.S. Corn Shipment: MFDS is testing all U.S. origin corn shipments to confirm the absence of Event 32. White corn, sweet corn, waxy corn and popcorn are excluded from the testing requirement. U.S. origin papaya and papaya products: MFDS does not allow imports of papaya or papaya products of U.S. origin as GE papaya produced in the United States has not been approved for human consumption by MFDS.
Approvals: There has been growing concern over the risk assessment process for LMO FFP. Specifically, some facets of the risk assessment process are considered to be redundant, as five agencies are involved in the approval of a single event, and occasionally lack scientific justification. This cumbersome consultation process is sometimes slow, contributing to delays in the final approval of new events.
Organics: Korea maintains a zero-tolerance policy for the inadvertent presence of biotech content in processed organic products. Despite hope that Korea would change this policy when making regulations for MAFRA's new certification program for processed organic products in 2014, MAFRA adopted MFDS's zero tolerance policy in their final regulation. Any organic products testing positive for GE material will be instructed to remove an organic claim from the product label and the National Agriculture Product Quality Service (NAQS) may investigate the case to see if there is any intentional violation.
A) Regulatory Framework
Korea ratified the Cartagena Protocol on Biosafety (CPB) on October 2, 2007. On January 1, 2008, Korea implemented the LMO Act, which is the implementing legislation for the CPB and the overarching law governing the country's biotechnology related rules and regulations.
The LMO Act has a fairly lengthy history prior to implementation. The Ministry of Trade, Industry and Energy (MOTIE, formerly the Ministry of Knowledge Economy [MKE]), which is the competent national authority, spearheaded the drafting of the Act and its underlying regulations back in early 2001. After several years and numerous iterations, MOTIE published drafts for public comment in September 2005. While the text of the Act and lower level regulations were finalized just six months later in March 2006, the regulations were not implemented until January 1, 2008. After several attempts, the LMO Act was finally revised in December 2012 with a few modifications including a revised definition of stacked events. Overall, however, it failed to address U.S. concerns regarding redundant consultation reviews and did not make a distinction between LMOs-FFP and LMOs for propagation. The revised Act went into effect on December 12, 2013.
Roles & Responsibilities of Government Ministries
Ministry of Trade, Industry and Energy (MOTIE): National competent authority for the CPB, responsible for the LMO Act and issues related to the development, production, import, export, sales, transportation, and storage of LMOs for industrial use.
Ministry of Foreign Affairs (MOFA): National focal point for the CPB.
Ministry of Agriculture, Food, and Rural Affairs (MAFRA): Authority for matters related to the import/export of agricultural/forestry/livestock LMOs.
Rural Development Administration (RDA) (overseen by MAFRA): ERAs for biotech crops, environmental risk consultation for LMOs and leading developer of biotechnology crops in Korea.
Animal, Plant and Fisheries Quarantine & Inspection Agency (QIA) (overseen by MAFRA): import inspection of LMOs for agricultural use at the port of entry.
National Agriculture Product Quality Service (NAQS) (overseen by MAFRA): Handles import approval of LMOs for feed use.
Ministry of Oceans and Fisheries (MOF): Authority for matters related to the trade of maritime LMOs including risk assessments for such LMOs.
National Fisheries Research & Development Institute (NFRDI), (overseen by MOF): Handles import approval of fisheries and consultations for LMOs for marine environment.
Ministry of Health and Welfare (MHW): Authority for matters related to the import/export of LMOs used for health and pharmaceutical purposes including human risk assessments of such LMOs.
Korea Center for Disease Control and Prevention (KCDC) (overseen by MHW): Oversees human risk consultation for LMOs.
Ministry of Food & Drug Safety (MFDS) (under the Prime Minister's Office): Authority for matters related to the import/export of LMOs for food, pharmaceutical, and medical devices; food safety approvals of biotechnology crops; and the enforcement of labeling requirements for non-processed and processed food products containing biotech ingredients.
Ministry of Environment (MOE): Authority for issues related to the trade of LMOs that are used for the purpose of environmental remediation or release into the natural environment including risk assessments for such LMOs, not including agricultural LMOs for planting.
National Institute of Ecology (NIE) (overseen by MOE): Handles import approval of LMOs under jurisdiction of MOE and environmental risk consultation for LMOs.
Ministry of Science, Information Communication Technology (ICT) & Future Planning (MSIP): Authority for issues related to the trade of LMOs that are used for testing and research including risk assessments for such LMOs.
Role and Membership of the Biosafety Committee and Its Political Implications
In accordance with Article 31 of the LMO Act, a Biosafety Committee was formed in 2008 under the Office of the Prime Minister. In accordance with the LMO Act revision issued on December 11, 2012, the committee was later moved under MOTIE in December 2013. The change of the Committee chair to the MOTIE Minister from the Prime Minister was not intended to downgrade the status of the committee but was meant to achieve more effective and efficient operation of the Committee. The Committee reviews the following factors relevant to the import and export of LMOs:
- Factors relevant to the implementation of the protocol
- Establishment and implementation of the safety management plan for LMOs
- Re-examination in accordance with the provisions of Article 18 and Article 22 of appeals by an applicant who fails to get import approval, etc.
- Factors relevant to legislation and notification pertinent to the safety management, import, and export, etc. of LMOs
- Factors relevant to the prevention of damage caused by LMOs and measures taken to mitigate damage caused by LMOs
- Factors requested for review by the Chair of the Committee or the head of the competent national authority.
The MOTIE Minister is the chair of the 15-20 member committee. Members include Vice Ministers from the seven relevant ministries noted above plus the Ministry of Planning and Finance (MOPF). Private sector specialists can also be members of the Committee. The Committee may have subcommittees and technical committees.
The most important role of the Committee is to reconcile different positions among the relevant ministries. As each relevant ministry holds authority and responsibility in its respective area, it may not be easy to reach consensus on some issues. In such cases, the MOTIE Minister as the Chair of the Committee can be called upon to resolve matters lacking consensus. While the frequency of meetings is not exactly known, it appears as though the committee meets very infrequently. The last meeting was conducted through document circulation rather than face to face in December 2014.
Regulatory decisions related to agricultural biotechnology are influenced by political pressure, mostly from vocal anti-biotech NGOs. Some of these outspoken organizations are appointed as members of the government's food safety and biotechnology risk review committees and use this position as a way to pressure the government to introduce more stringent biotech regulations. The draft revision to the Food Sanitation Act to expand biotech labeling requirements to any product made of biotech grain is a good example of the political influence of vocal anti-biotech NGOs.
Biotechnology crops, whether grown domestically or imported, are required to undergo a food safety assessment and an ERA. Of note, the ERA is sometimes referred to as a feed approval, though the review is largely focused on the impact to the environment, not animal health.
Several different agencies are involved in the overall assessment process. RDA conducts the ERAs to approve new events in feed grains. As part of the environmental assessment, RDA consults with three different agencies, including NIE, NFRDI, and KCDC. Meanwhile, MFDS conducts a safety assessment for food grains containing biotech events. The MFDS review process includes consultations with RDA, NIE and NFRDI.
The overlap between reviewing agencies, particularly between MFDS and KCDC, and redundant data requirements have led to confusion and unnecessary delays in the approval process. In response to continued requests to simplify the current approval process by streamlining the redundant and duplicative approval processes, Korea introduced a pilot project called “joint environmental consultation review." Korea combined committees of NFRDI and NIE and the joint committee reviewed one event in 2016. However, results of the joint review indicate that few time savings or data collection efficiencies were achieved.
MFDS has three categories of approval: full approval and two types of conditional approval. Full approval is given to biotech crops that are commercially produced and imported for human consumption. Conditional approval applies to those crops that have been discontinued or are not grown commercially for human consumption. As of October 2016, MFDS has granted food safety approval for 164 events including 144 crops, 18 food additives and two microorganisms. RDA has approved 135 events for use in feed out of a total of 158 submissions.
Although no product has been approved for commercial production in Korea, a local university funded by RDA approached its donor agency in 2008 to request approval to plant biotech grass used for landscaping purposes. The submission, initially turned down due to insufficient data, was re-submitted with requested data in October 2010. The developer again withdrew the submission in 2012 and submitted a new package with some modifications in late 2014. The package is currently under review by RDA.
C) Stacked Events Approval
MFDS does not require a full safety assessment for stacked events if they meet the following criteria:
- The traits being combined were already approved individually
- There is no difference in the given traits, intake amount, edible parts and processing method in the stacked event and the conventional non-biotech counterpart
- There is no crossbreeding among subspecies
The Consolidated Notice released in December 2007 includes a provision for ERAs for stacked events. The following documents need to be submitted to RDA:
1. Information to verify whether there is interaction of traits in nucleic acid inserted in the parental line
2. Available information pertinent to characteristics of the stacked event
3. Evaluation of 1 and 2 above
4. Confirmation from the developer who received approval for the parental event used in the stacked event and agreement for review of already submitted information for the parental event RDA reviews the submitted documents. If there is interaction between traits in the inserted nucleic acid of the parental line or other differences are noticed, RDA will then require an ERA. Otherwise, a full ERA is not required.
Korea reviews multi-trait stacked events with crop-based information rather than information for individual intermediate events. This means that intermediate events are not subject to the review unless they become commercialized.
The approval process for stacked events is becoming reason for concern. Both RDA and MFDS allow the submission of a dossier for stacked events after all parental single events are approved in
Korea. Considering the approval time needed for stacked events after submission, which is a minimum of 3 to 6 months and up to one year, developers have to delay commercialization of stacked events approved by USDA until Korea has finished approval.
D) Field Testing
RDA authorized contained field trials for 403 events in 2015. From January to November 2016, a total of 371 field trials were approved. Many of the approved field trials are for traits with resistance to environmental stress. RDA renews the field trial permits every year. The lion's share of field trials are for rice with many different traits, such as environmental stress resistance, enhanced nutritional qualities, and insect resistance. Field trials for peppers, beans, cabbages, and grass are also underway.
According to the Consolidated Notice, which is the implementing regulations of the LMO Act, in-country field tests are required for imported LMOs used as seed. For LMOs used as FFP, RDA will review the data from field trials conducted in the exporting country. However, if necessary, RDA may require in-country field tests for LMO FFPs.
The biotech crops being developed by RDA are subject to field trials and must follow the “Guidelines for Research and Handling of Recombinant Organisms Related to Agricultural Research." Biotech crops developed by private entities, including universities, should adhere to guidelines published by the Ministry of Health & Welfare, entitled “Guidelines for Research of Recombinant Organisms." The Consolidated Notice also includes guidelines for local biotech developers and laboratories to comply with during their research and development.
E) Innovative Biotechnologies
Korea has not determined the regulatory status of innovative biotechnologies (e.g. genome editing, amongst others). There is growing interest by scientists and regulators in how Korea should approach this issue. Korea is closely watching developments in foreign countries.
As noted earlier, biotech crops are not yet grown in Korea. As a result, regulators have not developed co-existence policies, which will undoubtedly be controversial with organic production continuing to increase each year.
With the restructuring of the Korean government in 2013 under the new administration, the authority over labeling of unprocessed biotech agricultural products was moved to MFDS from MAFRA. Now, MFDS is responsible for establishing biotech labeling guidelines for both unprocessed and processed products, and enforcing guidelines in the market place.
Both unprocessed biotech crops for human consumption and certain processed food products containing biotech ingredients must carry “genetically modified" (GM) food labels. The stated purpose behind biotech labeling is to respond to the consumers' right to know. Currently, there are very few products on the market with a “GM" label.
Similar to the situation in other countries, pressure from NGOs to mandate labeling requirements continues to grow. In response, MFDS initiated a biotech labeling effort in 2008 and 2012. However, such attempts were not realized due to feedback from the local food industry. In 2013, a total of three draft bills related to the Food Sanitation Act requiring expanded biotech labeling were submitted by lawmakers to the National Assembly. The detection of GE wheat in Oregon in 2013 added momentum to the local anti-biotech movement and these groups began to demand that the Korean government expand labeling requirements. A civic group called the “Citizen's Coalition for Economic Justice (CCCE)" formed the “Consumer Justice Center" in 2013. The center is headed by a former Agricultural Minister and has a goal of expanding biotech labeling under the pretext of the consumer's right to know. The center has been organizing meetings to debate labeling and keeps pressing MFDS to expand labeling requirements. The center also requested that MFDS provide the names of food manufacturers that use biotech grain and the volume of biotech grain used by each company. MFDS refused the request as it is considered confidential information. The center took MFDS to court and won in 2016. Thus, MFDS revealed the names of manufacturers and the volume of biotech grain per manufacturer.
In abolishing all three pending bills, lawmakers and MFDS made an alternative revision of the Food Sanitation Act on February 3, 2016. This revision expanded mandatory biotech labeling to any food products that contain detectable biotech ingredients. Under the current system, MFDS requires biotech labeling for products that contain biotech ingredients as one or more of the top five ingredients. MFDS removed the top five ingredient criteria and will begin requiring a label for any product that contains detectable biotech ingredients. Cooking oils and syrups will continue to be exempt from mandatory biotech labeling. This revision will go into effect on February 4, 2017.
To provide clarity on biotech labeling requirements that reflect changes in the Food Sanitation Act, MFDS issued a draft revision of Labeling Standards for Biotech Food in April 2016 and opened the comment period until June 20, 2016. In the draft revision, MFDS proposed the following:
- Not to allow “Non-GMO" or “GMO Free" claims for products made of conventional products that do not have biotech counterparts (e.g. apple, oranges, etc.)
- To require biotech labeling for products with different nutritional profile compared to conventional counterpart (e.g. High Oleic GE Soybean)
- To make clear the exemption of mandatory biotech labeling for products that do not contain a foreign protein or DNA
However, due to many comments and objections from local NGOs, MFDS had to re-publish the draft revision in June 2016 and extend the comment period until July 20, 2016. Local NGOs continued to push MFDS to expand mandatory biotech labeling to both detectable and non-detectable products, similar to the EU scheme. They also asked MFDS to allow “Non-GMO" or “GMO Free" claims for products with conventional products that do not have biotech counterparts. If MFDS allows such claims, any products made of local crops/fruits/vegetables can carry “Non-GMO" or “GMO Free" claims as Korea does not grow any biotech crops commercially in Korea. However, MFDS' position on this issue is that it will confuse and mislead consumers, and therefore such claims are prohibited. The draft revision of Labeling Standards for Biotech Food is still pending. MFDS plans to finalize it soon but no specific date of the final publication of Labeling Standards for Biotech Food has been determined.
Two new draft bills to the Food Sanitation Act to expand mandatory biotech labeling to all products made of biotech crops have been submitted to the National Assembly in August and November 2016, respectively. Post will provide any updates on those draft bills when it is available.
The local food industry is concerned that expanded biotech labeling would end-up misleading consumers, limit the available selection of products on the market, and increase production costs. For example, if implemented, food manufacturers would be unwilling to develop any food using these ingredients and supermarkets would shy away from carrying any GE-labeled product for fear of losing sales. The industry is also concerned that in the absence of scientifically verifiable measures there could be false labeling or documentation forgery for imported oil and syrups claiming to be “non-GMO" but actually made of biotech enhanced crops. The domestic industry is demanding that MFDS delay implementation of the expanded labeling requirements beyond February 4, 2017, until there are scientific methods available to detect biotech content or a system put in place that can prevent such falsely labeled products from entering Korea.
In April 2007, MIFAFF (a previous title of MAFRA) revised its Feed Manual requiring retail packaged animal feed products to carry a “GMO" label when the product contains biotech ingredients. This labeling requirement was enforced beginning on October 11, 2007. There have been no reported problems due to the fact that nearly all animal feed products contain biotech ingredients and are therefore subject to this labeling requirement.
In 2008, during the candlelight protests against U.S. beef, consumer groups learned that some of the country's corn processors would be bringing in biotech corn for processing for the first time because of the short supply of conventional corn and rising international grain prices. These groups threatened to boycott products from food manufacturers using biotech corn ingredients. In response, 21 large companies jointly declared that they would not use ingredients derived from biotech corn in their products.
GE Labeling Requirements for Bulk Grains
- Shipments consisting of 100 percent unprocessed biotech crops for human consumption are required to carry labels stating “GM 'commodity'" (e.g. “GM soybeans")
- Shipments that contain some biotech-enhanced crops are required to carry labels stating that the product “contains GM 'commodity'" (e.g. “contains GM soybeans")
- Shipments that may contain biotech-enhanced crops are required to carry labels stating that the product “may contain GM 'commodity'" (e.g. “may contain GM soybeans").
GE Labeling Requirements for Processed Products
- Products that contain biotech corn or soybeans, which comprise less than 100 percent of the product ingredients, are required to be labeled as “GM food" or “food containing GM corn or soybeans."
- Products that may contain biotech corn or soybeans are required to be labeled “May contain GM corn or soybeans."
- Corn or soybean products that are 100 percent biotech products are required to be labeled “GM" or “GM corn or soybeans."
Korea allows for up to three-percent unintentional presence of approved biotech components in unprocessed non-biotech products (e.g. conventional food grade soybeans) which carry an IP or government certificate. This three-percent tolerance of biotech components in raw materials is the default threshold for processed food products that are subject to biotech labeling requirements.
Intentional mixture of biotech ingredients triggers the labeling requirement even if the final level of biotech presence is within the three percent threshold. Grains and processed food products within the three percent threshold are required to submit full IP documentation or a certificate recognized by the exporting government to be exempted from biotech labeling requirements.
Use of Labels Such as Biotech-Free, Non-Biotech, “GMO-Free", or “Non-GMO": A “non-GMO" label is permitted if the product is 100-percent non-biotech. As a zero tolerance standard applies, any products tested positive for “GMOs" will be a violation of labeling standards. Therefore, MFDS does not encourage “non-GMO" or “GMO-free" labeling to prevent the misuse of such labels. MFDS does not allow these claims for a product that does not have a commercially available biotech counterpart. Importers must keep relevant documentation supporting their “non-GMO" claim. Such documents can include a testing certificate issued by MFDS accredited testing laboratories stating that there are no GE components present.
H) Monitoring and Testing
The National Institute of Environmental Research (NIER) under the Ministry of Environment (MOE) started monitoring for the presence of imported LMOs in the Korean environment in 2012. NIER collected and tested 626 samples of corn, soybean, canola and cotton countrywide. Of those samples, 42 samples from corn, canola and cotton were identified as LMOs. NIER ascertained that LMO plants were propagated from LMOs imported for FFPs that were inadvertently released during transportation in Korea. NIER continued monitoring in 2013. The National Institute of Ecology (NIE), which replaced NIER as the designated natural environmental risk assessment agency has continued to monitor the fallout of imported LMOs in the Korean environment since 2014. In 2015, they confirmed 51 samples of LMOs.
I) Low Level Presence Policy
Korea does not have a low level presence (LLP) policy. Instead, Korea uses the term “adventitious presence" in enforcing mandatory labeling and allows as much as 0.5% of the content of a non-LMO shipment to contain unapproved LMOs.
J) Additional Requirements
For biotechnology crops intended for FFP, no additional registration is required other than approval. For LMOs for propagation, however, the crop should complete the process to be approved as a seed.
K) Intellectual Property Rights
As previously mentioned, biotechnology crops are not commercially planted in Korea. However, intellectual property rights are protected under existing domestic regulations.
L) Cartagena Protocol Ratification
Korea ratified the Cartagena Protocol on Biosafety (CPB) on October 2, 2007 and implemented the LMO Act, the legislation implementing the CPB, on January 1, 2008. The first revision of the LMO Act was issued in December 2012 and the revised LMO Act went into effect on December 12, 2013. MOTIE also revised its implementing regulations to harmonize with the revised Act in December 2013 and the Consolidated Notice in July 2014. Despite the revision, which sought to improve the approval process, MOTIE failed to fully address concerns related to the redundancy of consultation reviews that the U.S. government has recommended for many years.
To address concerns from domestic industry and foreign trading partners on the “does contain" principle in the existing regulation, MOTIE revised the import approval application for LMOs for FFP, which is part of the Enforcement Regulations of the LMO Act, on April 30, 2013. The revised form clearly stipulates “may contain" principles for LMO FFP and therefore it eliminated concerns exporters and domestic importers had over the gaps between industry practice and principle in the written regulations. Korea allowed and continues to allow exporters to simply provide a list of all biotech events approved for use in Korea on the commercial invoice and importers can simply copy and paste the same list in the import application form.
M) International Treaties/Fora
Korea is actively participating in CODEX, IPPC, OIE, APEC and other meetings. Korea tends to loosely follow CODEX regulations in their safety assessment guidelines.
N) Related Issues
No further issues.
Part C: Marketing
A) Public/Private Opinions
Consumers are much more sensitive and generally negative towards the use of biotechnology to produce food and are therefore willing to pay more for non-GE food. Outspoken NGOs and the broadcast media tend to reinforce this negative image, vilifying foods made from biotech crops as 'franken food'.
As discussed above, the detection of GE wheat in Oregon in 2013 alarmed Korean consumers and media and was perceived as inadequate management of GE production in the United States. The detection gave momentum to a civic group called the “Citizen's Coalition for Economic Justice (CCCE)" to demand expanded biotech labeling under the pretext of the consumer's right to know. The Center has organized multiple meetings to debate expanded labeling and keeps pressing the National Assembly and MFDS to expand labeling requirements. To address concerns raised by consumers and end-users, the Korean Flour Millers Association temporarily suspended the purchase of U.S. origin wheat for about a month until MFDS released its second test results for GE wheat in wheat and wheat flour imported from the United States. In light of these sensitivities, many local food manufacturers are very reluctant to use biotech ingredients. In fact, on the heels of the 2008 beef protests, twenty-one large food conglomerates, including several multinational companies, declared themselves GE-free as a marketing ploy. Local retailers are likewise reluctant to carry GE-labeled foods since they do not want to put product on their shelves that will not sell and would inevitably draw public scrutiny. Another detection of GE wheat in Washington State in 2016 reinforced the perception that management of GE research and production is not adequate, creating the perception that the unintentional release of unapproved events may continue to happen.
Nonetheless, Korea imports substantial amounts of biotech food ingredients for further processing into vegetable oil, corn syrup, and other products that are currently exempt from the GM food labeling requirements. The general public, though, seems unaware of this fact.
B) Market Acceptance/Studies
There are contradictory views about biotechnology in the Korean marketplace. The public holds positive views on the use of biotechnology in human and animal research, bio-medicine, and in the treatment of disease while they tend to be negative towards its use in food production. Marketing Studies In July 2008, the Korea Consumer Union conducted a survey of National. Assemblymen to gauge lawmakers' awareness of biotechnology. The survey showed that the ruling conservative Grand National Party (GNP) was more favorable towards the technology compared to the opposition Democratic Party (DP). Overall, though, both the GNP and DP have a rather negative perception of biotechnology.
Over 50 percent of the lawmakers felt uneasy about eating biotech food and more than 75 percent said that biotech labeling should be required for cooking oil. These findings, though, seemed somewhat out of place since over 60 percent of the lawmakers were aware that Korean regulators conduct safety evaluations of each biotech crop used in food and feed before allowing it to come into the country.
While consumers are apparently reluctant to eat biotech crops, the survey revealed that the Assemblymen were less concerned about locally developed biotech crops. About 7 percent of GNP and 24 percent of DP Assemblymen thought Korea should stop development of biotech crops. This is a noteworthy finding since it shows that one of the keys to improving consumer confidence in biotech foods lies in the development and commercialization of a Korean biotech crop. As noted earlier, while research is currently underway to develop the country's first biotech crop, commercialization is still several years away under the most favorable circumstances.
In November 2015, the Korea Biosafety Clearing House (KBCH) conducted its eighth annual survey of 600 consumers nationwide to gauge public perceptions on biotechnology. The survey results showed that consumer awareness has continued to remain high while consumers still remain concerned over the safety of biotechnology. Over 45 percent answered that biotechnology would be beneficial to humans while 41 percent and 13 percent of respondents answered either neutral or not beneficial respectively. Over 59 percent answered that it was beneficial to curing diseases such as cancer and 23 percent answered that it might help solve food shortage issues. Of those who answered it was not beneficial, 42.5 percent of respondents questioned the safety of biotechnology to humans and 45 percent of the respondents thought that biotechnology used in making food was against nature.
The KBCH survey confirmed again that consumers were more favorable towards the use of the technology outside the agricultural sector. Over 82 percent and 79 percent of the respondents supported its use in the medical and bio-energy sectors respectively, while over 35 percent supported its use in livestock and 45 percent in food and agricultural products. Concerning consumer acceptance, only 35.2 percent of respondents answered that LMOs would be well accepted by the society. Over 69 percent of the respondents answered that it was necessary for Korea to develop LMOs while 41 percent of the respondents answered that it was necessary for Korea to grow biotech crops and 27 percent that it would produce biotech animals in the country. About 21 percent responded that it was necessary for Korea to import LMOs produced in foreign countries. Over 89 and 88 percent were in favor of labeling and strict import controls on biotech products, respectively.
About 17 percent of the respondents were interested in LMOs. However, over 65 percent of these respondents were interested because of their concern over the safety of LMOs. The respondents obtained information on LMOs mostly from TV, followed by internet news.
In November 2008, the KCBH conducted a nationwide survey of 1,082 researchers from various backgrounds to gauge the academic community's perception of biotechnology. The survey results showed that around 44 percent of the respondents understood LMOs well. Over 69 percent thought that GMO was the most recognizable term for LMO. Eighty-five percent of the respondents thought that LMOs would contribute to the development of human life. The survey also revealed that researchers were more positive about LMOs used for pharmaceutical purposes than for food use.
CHAPTER 2: ANIMAL BIOTECHNOLOGY
Part A. Production and Trade
A) Product Development
Korea is actively using genetic engineering for the development of animals that produce new biomedicines, bio-organs, etc. Korea is also using cloning technology to expand the number of animals with a high capacity to produce such useful materials and bio-organs. The research is being led by various government agencies and private entities including academia.
In 2016, MAFRA announced a plan called “2016 Promotion of Science and Technology for Agriculture, Forestry and Food." According to the plan, MAFRA will invest in R&D in seven selected areas, which include value-added agri-bio resources. MAFRA plans to invest 111 billion Korean won (approx. 110 million US dollars) for R&D in agri-bio resources. It will cover production of pigs producing bio-organs, production of special purpose dogs using cloning technology (sniffing dogs), and stem cell production technology, among others.
In 2010, MIFAFF (currently MAFRA) announced its overall plan for future growth engines for the life science industry in Korea. Biomedicine is one of the areas where considerable resources are being invested. RDA's 10 year Next Generation Bio-Green 21 Project launched on May 19, 2011, also focuses on development of biomedicines and bio-organs as one of the three top sectors.
The National Institute of Animal Science (NIAS) of RDA is focusing on the development of new bio materials using biotechnology, such bio-organs, securing diversity of animal genetic resources, developing high value added livestock products, developing renewable energy using livestock resources, with the goal of becoming a “world G7 livestock technology country." NIAS is conducting research to develop 24 different traits in two animals; 17 traits in swine and seven traits in chicken. These traits are designed to produce high value protein and anti-virus materials, swine producing material that can treat anemia, hemophilia, thrombus and chickens producing eggs with lactoferrin and antioxidant substances. NIAS produced two transformed mini pigs that can be used to produce bio-organs. RDA is also conducting research to develop four different traits using silk worm. Traits under development will enable production of silk in various natural colors, immune peptides that replace antibiotics in animal feed, and medicine for humans. In 2012, RDA succeeded in transplanting a heart and a kidney from a transformed mini pig into a monkey. As follow up research in 2014, RDA succeeded in transplanting a heart from a transformed pig called GalT KO+MCP with genes inhibiting hyperacular rejection and acute vascular rejection into a monkey. Despite significant effort, however, all this research remains in the development stage, still short of even the risk assessment stage. Currently, RDA does not have any plan to develop genetically-engineered or cloned animals for food use.
The Ministry of Science, Information Communication Technology (ICT) & Future Planning (MSIP) announced in July 2013 that they would invest 9.2 trillion won (approximately $8 billion) of R&D funding into science technology in the five years through 2016. MSIP designated 30 technologies for focused support during the five years, including one related to genetic resource technology for the development and commercialization of value added life science resources. MSIP will focus its other investment on the development of new biomedicine and stem cell and genome research. In line with the MSIP investment plan, MAFRA also announced a long and mid-term plan to promote agriculture technology in July 2013. In the plan, the technology to develop bio materials and transformed animals for the production of pharmaceutical products has been set as one of the sub-projects under the four major research areas that MAFRA will focus on. The four major areas are 1) strengthening global competitiveness, 2) creating a new growth engine, 3) ensuring a stable supply of food grain, and 4) improving public happiness. Under the category of creating a new growth engine, MAFRA and RDA will continue to develop new bio materials using animal biotechnology.
In 2013, a team of professors from multiple Korean and U.S. universities announced that they succeeded in the production of a cloned mini pig named “GI Blue" whose gene that causes acute immune rejection response was removed. This is another step toward the development of bio-organs and organ plantation in different species.
Private entities are also developing genetically-engineered animals that produce high value protein pharmaceuticals. In 2014, Choongbuk National University announced that they produced a transformed cloned pig with a trait that can control an expression timing of a particular protein. This technology will allow them to produce a great volume of proteins to cure people. In 2012, one pharmaceutical company announced that they produced 14 transformed pigs inserted with a human growth hormone gene (hGH) and those pigs produced milk in which hGH was expressed. This is one step forward to the development of a pharmaceutical product with hGH. Others are developing transgenic cattle that can produce lactoferrin and insulin, a fluorescent dog for human disease research, chickens that purportedly produce substances to cure leukemia and mini-pigs for production of bio organs.
In July, 2015, a team of professors from Korean and Chinese universities announced that they made a super pig which has higher muscle content than ordinary pigs using a gene editing technology. The team removed a gene called MSTN, which inhibits muscle growth, from a somatic cell and cloned pigs using nuclear transplantation with the edited gene. The team believes that the livestock industry might positively view pork with more muscle and high in protein.
B) Commercial Production
Despite active research by Korean scientists, Korea has yet to commercially produce any genetically-engineered animals. It is too early to estimate how close Korea is to commercial production. As for food use, Korean scientists are relatively unwilling to engage in research as they are concerned about consumer's acceptance of meat from genetically-engineered animals.
Korea does not export any biotech animal as Korea does not commercially produce any biotech animals.
Korea imports genetically engineered mice and e-coli for research.
Part B: Policy
A) Regulatory Framework
The LMO Act and its implementing regulations apply to the development and importation of genetically engineered animals. Pharmaceuticals produced from genetically-engineered animals are governed by the Pharmaceuticals Affairs Act. No specific regulation has been established for the management of genetically engineered animals.
B) Innovative Biotechnologies
Korea has not determined the regulatory status of innovative biotechnologies. There is growing interest on the part of scientists and regulators related to how Korea should approach this issue. Korea is closely watching developments in other countries.
C) Labeling and Traceability
MAFRA is responsible for the labeling and approval of genetically-engineered animals, but has not yet established any regulations. MFDS is responsible for the safety evaluation of genetically-engineered animals and fishery products for human consumption under its GMO safety evaluation guidelines.
D) Intellectual Property Rights
As noted above, biotechnology animals are not commercially grown in Korea. However, intellectual property rights are protected under existing domestic regulations.
E) International Treaties/Fora
Not specifically related to genetically-engineered animals, but Korea is actively participating in CODEX, IPPC, OIE, APEC and other meetings. Korea is trying to loosely follow CODEX regulations in their safety assessment guidelines.
F) Related Issues
No related issues have been identified.
Part C: Marketing
A) Public/Private Opinions
Many Koreans believe that biotechnology is an important frontier for the economic development of Korea in the 21st century. Proponents have had some success in making the case that biotechnology could be an engine for growth and could solve public health and environmental problems. Korea continues to expand investment in biotechnology research and development for biomaterial, biomedicine and organs, and gene therapy, among others.
Despite the Korean government's support for biotechnology research, the Korean public has a negative perception of crops and foods produced through biotechnology. For meat or food from genetically-engineered animals, it is expected that the public will have even more serious concerns. Consequently, the majority of government funding for biotechnology research is directed toward non-agricultural projects such as biomedicine, stem cell research, cloning, and gene therapy. Koreans in general maintain a positive view towards non-agricultural biotechnology and believe biotechnology will play an important role in the country's economic development.
B) Market Acceptance/Studies
There are contradictory views about biotechnology in the Korean marketplace. The public holds positive views about the use of biotechnology in human and animal research, bio-medicine, and in the treatment of disease while they tend to be negative towards the use of the technology to produce food. No market studies are available.